Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zogenix Inc.

www.zogenix.com

Latest From Zogenix Inc.

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016

Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.

Financing Business Strategies

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Stellar Zogenix Phase III Epilepsy Data Lift ZX008's Competitive Position

Company is planning to file in the second half with two pivotal studies, but says it is "worth exploring" with the US FDA whether data from the first study could support an application.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SJ2 Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Zogenix Inc.
  • Senior Management
  • Stephen J Farr, PhD, Pres. & CEO
    Michael P Smith, EVP, CFO, Treasurer & Secretary
    Bradley S Galer, MD, EVP, CMO
    Gail M Farfel, PhD, EVP, Chief Dev. Officer
  • Contact Info
  • Zogenix Inc.
    Phone: (858) 259-1165
    5858 Horton St.
    Ste. 455
    Emeryville, CA 94608
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register